The Protocol Review and Monitoring System (PRMS) in the University of Colorado Cancer Center’s Clinical Trials Office is under new leadership.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
The Protocol Review and Monitoring System (PRMS) in the University of Colorado Cancer Center’s Clinical Trials Office is under new leadership.
Community Cancer Magazine Leadership
Two important numbers to keep in mind are that 50.5% of the U.S. population is female, and that cancer will account for more than 606,000 deaths in the United States this year, making it the second-leading cause of death.
Thomas Flaig, MD, has been named director of the Academic Urology Research Investigators Consortium, an oncology consortium for genito-urinary cancers.
Thomas Flaig, MD, vice chancellor of research for CU Denver and CU Cancer Center member, discusses some of the current NCCN guidelines in bladder cancer.
About one out of every two Medicare patients with non-small cell lung cancer does not get the appropriate imaging before receiving radiation therapy.
The 2022 San Antonio Breast Cancer Symposium highlighted research and treatments for HER2-negative, HER2-low, and HER2-positive breast cancer.
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2022 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.